TG Therapeutics Inc. (NASDAQ:TGTX) reached a new 52-week low on Monday . The company traded as low as $5.61 and last traded at $5.84, with a volume of 169,566 shares changing hands. The stock had previously closed at $5.86.

A number of equities research analysts have recently weighed in on the company. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research note on Monday, June 13th. Zacks Investment Research downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. Brean Capital restated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, May 31st. Roth Capital restated a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a report on Thursday, June 9th. Finally, SunTrust Banks Inc. assumed coverage on TG Therapeutics in a report on Friday, May 27th. They set a “buy” rating and a $18.00 price target on the stock. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $22.33.

The firm has a 50-day moving average price of $6.80 and a 200-day moving average price of $8.34. The stock’s market cap is $321.51 million.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.08. Analysts expect that TG Therapeutics Inc. will post ($1.15) earnings per share for the current fiscal year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund boosted its position in shares of TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned 0.43% of TG Therapeutics worth $2,671,000 at the end of the most recent reporting period.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.